 |
Timothy A. Benke
Associate Professor
M.D./Ph.D., 1995, Baylor College of Medicine
Mechanisms of synaptic plasticity and impacts of development and epilepsy. |
 |
Elan Z. Eisenmesser
Assistant Professor
Ph.D., 1998, Purdue Univ.
Viral protein/host protein interactions, enzyme dynamics, and ligand/receptor interactions involved in cancer progression. |
 |
Paul V. Fennessey
Professor
Ph.D., 1968, Massachusetts Institute of Technology
Solutions to clinical problems using stable isotopes and mass spectrometry. |
 |
Curt R. Freed
Professor
M.D., 1969, Harvard Univ.
The dynamic role of dopamine in movement; neural transplantation for Parkinson’s disease. |
 |
Robert M.D. Freedman
Professor
M.D., 1972, Harvard Univ.
Central nervous system physiology and pharmacology and its application to clinical psychiatry. |
 |
Anthony N. Gerber
Professor
M.D., Ph.D., 1998, Univ. of Washington
Targeting the glucocorticoid receptor for the treatment of inflammatory disorders of the lung such as asthma.
|
 |
Lynn E. Heasley
Professor
Ph.D., 1985, Univ. of California, San Diego
Investigating the role of MAP kinases and specific receptor tyrosine kinases in normal and transformed growth of lung epithelial cells using techniques of molecular and cell biology in lung epithelial cells and human lung cancer cell lines. |
 |
Peter M. Henson
Professor
Ph.D., 1967, Cambridge Univ., UK
Inflammatory process as a paradigm of complex interacting cell networks and communication molecules and as a component of human diseases. |
 |
Paco Herson
Associate Professor
Ph.D., 1999, Univ. of Aberdeen, UK
Basic translational research using neurophysiology, biochemistry, molecular biology, histology and neuro-behavior to elucidate the mechanisms of neuronal injury and identify therapeutic targets for protection and repair.
|
 |
Robert S. Hodges
Professor
Ph.D., 1971, Univ. of Alberta
Structure-function studies of multi-protein complexes; de novo design of model proteins to test our understanding of protein folding and structure and to design proteins with the desired biological/immunological activities; synthetic peptide vaccines and . |
 |
John W. Kappler
Professor
Ph.D., 1970, Brandeis Univ.
The study of the interaction between the T cell receptor and its signal ligands. |
 |
Jeffrey S. Kieft
Associate Professor
Ph.D., 1997, Univ. of California, Berkeley
The way by which viral RNAs, with their diverse and dynamic structures, can hijack the machinery of an infected cell and using this information to understand basic biological processes.. |
 |
Christina C. Leslie
Professor
Ph.D., 1975, Univ. of Georgia
Signal transduction mechanisms regulating phospholipase A2 activation and the production of lipid mediators of inflammation. |
 |
Chuan-Yuan Li
Professor
Ph.D., 1993, Harvard Univ.
Molecular mechanisms of tumor response to therapy; roles of stem cells in tumor response to therapy. |
 |
Timothy A. McKinsey
Associate Professor
Ph.D., 1998, Vanderbilt Univ.
Epigenetic regulation of heart failure; signaling and transcriptional mechanisms of muscle disease. |
 |
Raphael A. Nemenoff
Professor
Ph.D., 1977, Cornell Univ.
Signaling pathways controlling growth and differentiation of vascular smooth muscle cells; Role of eicosanoids in lung cancer. |
 |
Dennis R. Petersen
Professor
Ph.D., 1974, Univ. of Wyoming
Molecular mechanisms of chemical and drug toxicity. |
 |
Assistant Professor
Ph.D., 1998, Thomas Jefferson Univ.
The various biological functions regulated by glycogen synthase kinase-3 (Gsk-3) isoforms, and the ketogenic diet, which is used to treat epilepsy in children. |
 |
J. David Port
Professor
Ph.D., 1989, Univ. of Utah
G-protein linked receptors and their regulation; regulation of mRNA stability. |
 |
Assistant Professor
Ph.D., 1999, Colorado State Univ.
We are interested in the cellular and molecular machinery responsible for cardiac pacemaking and its regulation by the autonomic nervous system. |
 |
David W.H. Riches
Professor
Ph.D., 1979, Univ. of Birmingham
Signal transduction by TNF receptor family members and their involvement in macrophage development; Regulation of myofibroblast and macrophage apoptosis and survival in pulmonary fibrosis and cystic fibrosis. |
 |
Natalie J. Serkova
Associate Professor
Ph.D., 1996, Univ. of Bremen
Animal Imaging (MRI, PET, CT); Magnetic Resonance Spectroscopy (MRS) based metabonomics; Cancer Metabolism and Physiology; Anti-Cancer Drugs; Ischemia/Reperfusion in Organs. |
 |
Neurogenomics; disease gene discovery; human genome evolution and variation. |
 |
Kunhua Song
Assistant Professor
Ph.D., 2007, Univ. of Texas Southwestern Medical Center
Using stem cells as a tool in the treatment of heart disease. |
 |
Dan TheodorescuProfessor and Director of the Univ. of Colorado Comprehensive Cancer CenterM.D., 1986, Queen's Univ. Faculty of Health Sciences; Ph.D., 1993, Univ. of Toronto
I'm a physician scientist. Our translational molecular biology laboratory focuses on identifying the molecular mechanisms leading to bladder cancer metastasis and their potential applications to patients with this disease. Our group is at the forefront of the development of biomarkers and therapeutics in bladder cancer. My clinical practice is limited to bladder cancer management including surgery such as radical cystectomy using state of the art robotic techniques (i.e. da Vinci). |
|
Rubin Tuder
Professor
M.D., 1979, São Paulo University of Medicine
Overall goals are to define the mechanisms of COPD pathogenesis and the molecular, cellular, and histopathological features of Pulmonary Hypertension. Our lab studies the pathogenesis of cigarette smoke induced emphysema and its underlying mechanisms, including the role of RTP-801 and adipocytokine, as well as his investigation in the pathogenesis of schistosomiasis-related pulmonary hypertension and development of targeted methods and treatment of pulmonary hypertension.
|
 |
Dennis R. Voelker
Professor
Ph.D., 1978, Oak Ridge National Laboratory
Phospholipid transport processes in eukaryotic cells. Pulmonary surfactant proteins – structure and function. |
 |
TGF-beta signal transduction, molecular mechanisms of cancer development and progression, functions of tumor suppressors and oncogenes. |
 |
Defining the molecular signaling mechanisms regulating vascular smooth muscle cell function in the setting of vascular fibroproliferative diseases, including restenosis and pulmonary hypertension.
|